# Ardent Health, Inc.: Form 10-Q for the period ended Sep 30, 2024

- Company: [Ardent Health, Inc.](/companies/ardt.md) (CIK 1756655)
- Form: 10-Q
- Filed: 2024-11-07
- Accepted by EDGAR: Nov 7, 2024, 16:32 ET
- Period: 2024-09-30
- Accession: 0001756655-24-000017
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1756655/000175665524000017/ardt-20240930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1756655/000175665524000017/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2024-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2024-07-01 to 2024-09-30 | $1.45bn | us-gaap:Revenues |
| Revenue | 9 months, 2024-01-01 to 2024-09-30 | $4.36bn | us-gaap:Revenues |
| Income tax | 3 months, 2024-07-01 to 2024-09-30 | $11.1m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2024-01-01 to 2024-09-30 | $37.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2024-07-01 to 2024-09-30 | $26.3m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2024-01-01 to 2024-09-30 | $96.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2024-07-01 to 2024-09-30 | $0.19 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2024-01-01 to 2024-09-30 | $0.74 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2024-07-01 to 2024-09-30 | $0.19 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2024-01-01 to 2024-09-30 | $0.74 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2024-07-01 to 2024-09-30 | 137,542,995 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2024-01-01 to 2024-09-30 | 130,022,643 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2024-01-01 to 2024-09-30 | $195.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2024-09-30 | $563.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2024-09-30 | $1.69bn | us-gaap:AssetsCurrent |
| Total assets | at 2024-09-30 | $4.80bn | us-gaap:Assets |
| Current liabilities | at 2024-09-30 | $887.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2024-09-30 | $3.41bn | us-gaap:Liabilities |
| Long-term debt | at 2024-09-30 | $1.08bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2024-09-30 | $12.2m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2024-09-30 | $1.01bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 94,916 characters.

### RESULTS OF OPERATIONS

#### Management's discussion and analysis of our financial condition and results of operations should be read in conjunction with

#### our interim unaudited condensed consolidated financial statements and related notes contained elsewhere in this Quarterly

#### Report on Form 10-Q for the quarter ended September 30, 2024 (this "Quarterly Report") and our annual financial

#### statements for the year ended December 31, 2023 included in our final prospectus dated July 17, 2024, filed with the

#### Securities and Exchange Commission (the "SEC") on July 18, 2024 pursuant to Rule 424(b) (the "Final Prospectus") under

#### the Securities Act of 1933, as amended (the "Securities Act"). The following discussion includes forward-looking statements

#### that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our

#### results to differ materially from those expressed or implied by such forward-looking statements. When reviewing the

#### discussion below, you should keep in mind the substantial risks and uncertainties that could impact our business. In

#### particular, we encourage you to review the risks and uncertainties described in the section titled “Risk Factors” included

#### elsewhere in this Quarterly Report and our Final Prospectus. These risks and uncertainties could cause actual results to

#### differ materially from those projected in forward-looking statements contained in this Quarterly Report or implied by past

#### results and trends. Our historical results are not necessarily indicative of the results that may be expected for any period in

#### the future, and our interim results are not necessarily indicative of the results we expect for the full fiscal year or any other

#### period.

#### Unless otherwise indicated, all relevant financial and statistical information included herein relates to our consolidated

#### operations. Additionally, unless the context indicates otherwise, Ardent Health Partners, Inc. and its affiliates are referred to

#### in this section as “we,” “our,” or “us.”

### Forward-Looking Statements

This Quarterly Report may contain certain “forward-looking statements,” as that term is defined in the U.S. federal securities

laws. These forward-looking statements include, but are not limited to, statements other than statements of historical facts,

including, among others, statements relating to our future financial performance, our business prospects and strategy,

anticipated financial position, liquidity and capital needs, the industry in which we operate and other similar matters. Words

such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “could,” “would,” “will,”

“may,” “can,” “continue,” “potential,” “should” and the negative of these terms or other comparable terminology often

identify forward-looking statements. These forward-looking statements are not guarantees of future performance and are

subject to risks and uncertainties that could cause actual results to differ materially from the results contemplated by the

forward-looking statements, including the risk factors and other cautionary statements described under the heading “Risk

Factors” included in this Quarterly Report and those included within our Final Prospectus. Factors, risks, and uncertainties

that could cause actual outcomes and results to be materially different from those contemplated include, among others: (1)

changes in government healthcare programs, including Medicare and Medicaid and supplemental payment programs and

state directed payment arrangements; (2) reduction in the reimbursement rates paid by commercial payors, our inability to

retain and negotiate favorable contracts with private third-party payors, or an increasing volume of uninsured or underinsured

patients; (3) the highly competitive nature of the healthcare industry; (4) inability to recruit and retain quality physicians, as

well as increasing cost to contract with hospital-based physicians; (5) increased labor costs resulting from increased

competition for staffing or a continued or increased shortage of experienced nurses; (6) changes to physician utilization

practices and treatment methodologies and third-party payor controls designed to reduce inpatient services or surgical

procedures that impact demand for medical services; (7) continued industry trends toward value-based purchasing, third party

payor consolidation and care coordination among healthcare providers; (8) loss of key personnel, including key members of

our senior management team; (9) our failure to comply with complex laws and regulations applicable to the healthcare

industry or to adjust our operations in response to changing laws and regulations; (10) inability to successfully complete

acquisitions or strategic joint ventures ("JVs") or inability to realize all of the anticipated benefits, including anticipated

synergies, of past acquisitions and the risk that transactions may not receive necessary government clearances; (11) failure to

maintain existing relationships with JV partners or enter into relationships with additional healthcare system partners; (12) the

impact of known and unknown claims brought against our hospitals, physician practices, outpatient facilities or other

business operations or against healthcare providers who provide services at our facilities; (13) the impact of government

investigations, claims, audits, whistleblower and other litigation; (14) the impact of any security incidents affecting us or any

third-party vendor upon which we rely; (15) inability or delay in our efforts to construct, acquire, sell, renovate or expand our

healthcare facilities; (16) our failure to comply with federal and state laws relating to Medicare and Medicaid enrollment,

permit, licensing and accreditation requirements, or the expansion of existing or the enactment of new laws or regulation

relating to permit, licensing and accreditation requirements; (17) failure to obtain drugs and medical supplies at favorable

prices or sufficient volumes; (18) operational, legal and financial risks associated with outsourcing functions to third parties;

(19) sensitivity to regulatory, economic and competitive conditions in the states in which our operations are heavily

23

concentrated; (20) decreased demand for our services provided due to factors beyond our control, such as seasonal

fluctuations in the severity of critical illnesses, pandemic, epidemic or widespread health crisis; (21) inability to accurately

estimate market opportunity and forecasts of market growth; (22) general economic and business conditions, both nationally

and in the regions in which we operate; (23) the impact of seasonal or severe weather conditions and climate change; (24)

inability to demonstrate meaningful use of Electronic Health Record ("EHR") technology; (25) inability to continually

enhance our hospitals with the most recent technological advances in diagnostic and surgical equipment; (26) effects of

current and future health reform initiatives, including the Affordable Care Act, and the potential for changes to the Affordable

Care Act, its implementation or its interpretation (including through executive orders and court challenges); (27) legal and

regulatory restrictions on certain of our hospitals that have physician owners; (28) risks related to the Ventas Master Lease

and its restrictions and limitations on our business; (29) the impact of our significant indebtedness, including our ability to

comply with certain debt covenants and other significant operating and financial restrictions imposed on us by the agreements

governing our indebtedness, and the effects that variable interest rates, and general economic factors could have on our

operations, including our potential inability to service our indebtedness; (30) conflicts of interest with certain of our existing

large stockholders; (31) effects of changes in federal tax laws; (32) increased costs as a result of operating as a public

company; (33) risks related to maintaining an effective system of internal controls; (34) volatility of our share price and size

of the public market for our common stock; (35) our guidance differing from actual operating and financial performance; (36)

the results of our efforts to use technology, including artificial intelligence, to drive efficiencies and quality initiatives and

enhance patient experience; (37) the impact of recent decisions of the U.S. Supreme Court regarding the actions of federal

agencies; and (38) other risk factors described in our filings with the SEC.

We caution you that the foregoing list may not contain all of the forward-looking statements made in this Quarterly Report.

You should not rely upon forward-looking statements as predictions of future events.

The forward-looking statements in this Quarterly Report are based on management’s current beliefs, expectations, and

projections about future events and trends affecting our business, results of operations, financial condition, and prospects.

These statements are subject to risks, uncertainties, and other factors described in the “Risk Factors” section and elsewhere in

this Quarterly Report. We operate in a competitive and rapidly changing environment where new risks and uncertainties can

emerge, making it impossible to predict all potential impacts on our forward-looking statements. Consequently, actual results

may differ materially from those described. The forward-looking statements pertain only to the date they are made, and we do

not undertake any obligation to update them to reflect new information or events unless required by law. You are advised not

to place undue reliance on these statements and to consult any additional disclosures we may provide through our other

filings with the SEC, such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form

8-K.

### Overview

Ardent is a leading provider of healthcare services in the United States, operating in eight growing mid-sized urban markets

across six states: Texas, Oklahoma, New Mexico, New Jersey, Idaho and Kansas. We deliver care through a system of 30

acute care hospitals and more than 200 sites of care with 1,808 employed and affiliated providers as of September 30, 2024,

an increase of 3.3% compared to September 30, 2023. Affiliated providers are physicians and advanced practice providers

with whom we contract for services through a professional services agreement or other independent contractor agreement.

We hold a leading position in a majority of our markets, and we believe we are one of the leading healthcare systems based

on market share and our integrated network of hospitals, ambulatory facilities, and physician practices. We operate either

independently or in partnership with premier academic medical centers, large not-for-profit hospital systems, community

physicians, and a community foundation through our well-established and differentiated JV model. Collectively, we operate

as a unified organization with a consumer-centric approach to caring for our patients and our communities. Our strategic JV

partners offer us significant advantages, including expanded access points, clinical talent availability, local brand recognition,

and scale that enable us to accelerate market penetration. We believe that we help our partners enhance their network and

regional presence through our operational acumen. We strive to strengthen clinical services, drive operating improvements,

and centrally manage operations to optimize hospital performance and enhance patient care. In each of these partnerships, we

are the majority owner and serve as the day-to-day operator.

24

### Recent Developments

### Term Loan B Facility Repricing

On September 18, 2024, we executed an amendment to reprice our Term Loan B Facility credit agreement (the "Term Loan

B Credit Agreement"). The repricing reduced the applicable interest rate by 50 basis points from Term SOFR plus 3.25% to

Term SOFR plus 2.75% and eliminated the credit spread adjustment. No modifications were made to the maturity of the

loans as a result of the repricing and all other terms were substantially unchanged.

### Initial Public Offering and Corporate Conversion

On July 19, 2024, we completed an initial public offering of 12,000,000 shares of our common stock (the "IPO"), at a public

offering price of $16.00 per share for aggregate gross proceeds of $192.0 million and net proceeds of approximately

$181.4 million after deducting underwriting discounts and commissions of approximately $10.6 million. The IPO provided

the underwriters with an option to purchase up to an additional 1,800,000 shares of our common stock, which was fully

exercised by the underwriters, and, on July 30, 2024, we issued 1,800,000 additional shares of common stock at $16.00 per

share for additional net proceeds of approximately $27.2 million, after deducting underwriting discounts and commissions of

approximately $1.6 million. Our common stock is listed on the New York Stock Exchange under the symbol “ARDT”.

On July 17, 2024, in connection with the IPO and immediately prior to the effectiveness of our registration statement on

Form S-1, we converted from a Delaware limited liability company into a Delaware corporation by means of a statutory

conversion (the “Corporate Conversion”) and changed our name to Ardent Health Partners, Inc. As a result of the Corporate

Conversion, the outstanding limited liability company membership units and vested profits interest units were converted into

120,937,099 shares of common stock and outstanding unvested profits interest units were converted into 2,848,027 shares of

restricted common stock. Immediately following the Corporate Conversion, ALH Holdings, LLC, a subsidiary of Ventas, Inc.

("Ventas"), contributed all of its outstanding common stock in AHP Health Partners, Inc. ("AHP Health Partners"), our direct

subsidiary, to Ardent Health Partners, Inc. in exchange for 5,178,202 shares of common stock of Ardent Health Partners, Inc.

(the "ALH Contribution"). The Corporate Conversion and the ALH Contribution have been retrospectively applied to prior

periods herein for the purposes of calculating basic and diluted net income per share. Our certificate of incorporation

authorizes 750,000,000 shares of common stock and 50,000,000 shares of preferred stock, each with a $0.01 par value per

share.

### ABL Credit Agreement Amendment and Term Loan B Facility Prepayment

On June 26, 2024, we executed an amendment to our ABL Credit Agreement to increase the revolving commitment by

$100.0 million to $325.0 million and extend the maturity date to June 26, 2029. Concurrent with the execution of this

amendment on June 26, 2024, we also prepaid $100.0 million of the outstanding principal on our Term Loan B Facility. The

$100.0 million prepayment was applied in direct order of maturities of future payments, and no modification was made to the

Term Loan B Facility as a result of this prepayment.

### 2024 Supplemental Payment Program Updates

A new Oklahoma directed payment program (the “Oklahoma DPP”) became effective on April 1, 2024. Under the Oklahoma

DPP, hospitals receive directed payments in accordance with Oklahoma’s new Medicaid managed care delivery system,

resulting in reimbursement near the average commercial rate. The existing upper payment limit component of Oklahoma’s

Supplemental Hospital Offset Payment Program will remain in place for certain categories of Medicaid patients that continue

to be enrolled in Oklahoma’s traditional Medicaid Fee for Service program. We have recognized total revenue of $48.6

million under the Oklahoma DPP from the April 1, 2024 effective date through September 30, 2024.

In March 2024, New Mexico’s Healthcare Delivery and Access Act (the “New Mexico HDA Act”) was signed into law.

Subject to approval by the Center for Medicare & Medicaid Services (“CMS”), the New Mexico HDA Act would provide

directed payments for hospitals that serve patients in New Mexico’s Medicaid managed care delivery system, resulting in

reimbursement near the average commercial rate, and once approved, is expected to represent a material rate uplift for us.

25

The directed payment program under the New Mexico HDA Act was submitted to CMS for approval on August 5, 2024, with

a requested effective date of July 1, 2024. The program is still under CMS review.

We believe the preliminary estimate of our net benefit under the Oklahoma DPP and the New Mexico HDA Act to be in

excess of $150 million on an annualized basis, subject to change, non-recurrence, and adjustment for potential quality

performance requirements.

### Cybersecurity Incident

In November 2023, we determined that a ransomware cybersecurity incident had impacted and disrupted a number of our

operational and information technology systems (the “Cybersecurity Incident”). Upon detecting the ransomware, we quickly

activated our incident response protocols and implemented a series of containment and remediation measures, including

engaging the services of cybersecurity experts and incident response professionals. We also promptly launched an

investigation, engaged external counsel to support the investigation and involved federal and state law enforcement. During

this time, our hospitals remained operational and continued to deliver patient care utilizing established downtime procedures;

however, we advised local EMS systems and other providers to divert emergency ambulance transports to other facilities for

a few days until the Cybersecurity Incident had been contained. As a result of our investigation, we determined that the

unauthorized actor acquired a copy of certain personal information and protected health information of a limited number of

our patients and personal information of certain of our employees, but did not gain access to our EHR platform. We have

cooperated with law enforcement authorities that have made inquiries into the Cybersecurity Incident, and we have been in

contact with, and complied with, the requirements of various governmental authorities that require notification of such

incidents. Additionally, because of the time taken to contain and remediate the Cybersecurity Incident, our online electronic

billing systems were not functioning at their full capacities and certain billing, reimbursement and payment functions were

delayed.

We estimate the Cybersecurity Incident had an adverse pre-tax impact of approximately $74 million during the year ended

December 31, 2023. This estimate includes lost revenue from the associated business interruption and costs to remediate the

issue, net of insurance proceeds. For the three months ended December 31, 2023, we also experienced decreases in

admissions, surgeries (both inpatient and outpatient) and emergency room visits of 2.5%, 2.1% and 5.7%, respectively,

compared to the three months ended December 31, 2022, which, prior to the Cybersecurity Incident, were estimated to have

increased by 4.1%, 5.5% and 3.3%, respectively, compared to the same period in 2022. While our operations were no longer

materially disrupted as of September 30, 2024, we continued to experience delays in billing claims and obtaining

reimbursements and payments through the first quarter of 2024, and will incur certain expenses related to the Cybersecurity

Incident, including expenses to defend claims brought by individuals and other expenses related to the Cybersecurity

Incident. On October 4, 2024, we executed a settlement agreement to resolve the consolidated class action litigation. On

October 9, 2024, the Court preliminarily approved the settlement and set the hearing for the Court’s final approval of the

settlement for August 1, 2025. Settlement of the consolidated case on the agreed terms will require us to make cash

settlement payments that will not have a material impact on our results of operations, financial position or liquidity.

### Pure Health Equity Investment

On May 1, 2023, an affiliate of Pure Health Holding PJSC (“Pure Health”) purchased an equity interest representing 25.0%

of the total combined voting power of Ardent Health Partners, LLC from the unit holders at the time for approximately $500

million. In connection with Pure Health’s investment, unit holders were eligible to exercise tag-along rights to sell a

proportionate share of their individual equity ownership interest in Ardent Health Partners, LLC and AHP Health Partners,

our direct subsidiary. Ventas, a common unit holder that beneficially owned a percentage of our outstanding membership

interests and maintained a seat on our board of managers, making Ventas a related party, exercised its tag-along right to sell

its proportionate share of interest in both Ardent Health Partners, LLC and AHP Health Partners. Ventas sold approximately

24% of its ownership interest in Ardent Health Partners, LLC for $24.2 million in total cash proceeds. Additionally, to fulfill

Ventas’ right to sell its proportionate share of noncontrolling ownership interest in AHP Health Partners, we exercised our

right to repurchase those shares from Ventas for $26.0 million concurrent with Pure Health’s purchase of a minority interest

in Ardent Health Partners, LLC. The carrying value of Ventas’ noncontrolling interest was adjusted proportionate to the

shares repurchased to reflect the change in ownership of AHP Health Partners, with the difference between the fair value of

the consideration paid and the amount by which noncontrolling interest was adjusted recognized in equity attributable to

Ardent Health Partners, LLC. As of September 30, 2024, following the consummation of the IPO and the underwriters'

26

exercise of their option to purchase additional shares, Pure Health and Ventas beneficially owned approximately 21.2% and

6.5%, respectively, of our outstanding common stock.

### Key Factors Impacting Our Results of Operations

### Staffing and Labor Trends

Our operations are dependent on the efforts, abilities and experience of our management and medical support personnel, such

as nurses, pharmacists and lab technicians, as well as our physicians. We compete with other healthcare providers in

recruiting and retaining qualified management and support personnel responsible for the daily operations of each of our

hospitals and other facilities, including nurses and other non-physician healthcare professionals. At times, the availability of

nurses and other medical support personnel has been a significant operating issue for healthcare providers, including at

certain of our facilities. The impact of labor shortages across the healthcare industry may result in other healthcare facilities,

such as nursing homes, limiting admissions, which may constrain our ability to discharge patients to such facilities and

further exacerbate the demand on our resources, supplies and staffing.

We contract with various third parties who provide hospital-based physicians. Third-party providers of hospital-based

physicians, including those with whom we contract, have experienced significant disruption in the form of regulatory

changes, including those stemming from enactment of the No Surprises Act, challenging labor market conditions resulting

from a shortage of physicians and inflationary wage-related pressures, as well as increased competition through consolidation

of physician groups. In some instances, providers of outsourced medical specialists have become insolvent and unable to

fulfill their contracts with us for providing hospital-based physicians. The success of our hospitals depends in part on the

adequacy of staffing, including through contracts with third parties. If we are unable to adequately contract with providers, or

the providers with whom we contract become unable to fulfill their contracts, our admissions may decrease, and our operating

performance, capacity and growth prospects may be adversely affected. Further, our efforts to mitigate the potential impact

on our business from third-party providers who are unable to fulfill their contracts to provide hospital-based physicians,

including through acquisitions of outsourced medical specialist businesses, employment of physicians and re-negotiation or

assumption of existing contracts, may be unsuccessful. These developments with respect to providers of outsourced medical

specialists, and our inability to effectively respond to and mitigate the potential impact of such developments, may disrupt our

ability to provide healthcare services, which may adversely impact our business, financial condition and results of operations.

We also depend on the available labor pool of semi-skilled and unskilled employees in each of the markets in which we

operate. In some of our markets, employers across various industries have increased minimum wages, which has created

more competition and, in some cases, higher labor costs for this sector of employees.

### Seasonality

We typically experience higher patient volumes and revenue in the fourth quarter of each year in our acute care facilities. We

typically experience such seasonal volume and revenue peaks because more people generally become ill during the winter

months, which in turn results in significant increases in the number of patients we treat during those months. In addition,

revenue in the fourth quarter is also impacted by increased utilization of services due to annual deductibles, which are not

usually met until later in the year, and patient utilization of their healthcare benefits before they expire at year-end.

### Inflation

The healthcare industry is labor intensive. Wages and other expenses increase during periods of inflation and when labor

shortages occur in the marketplace. In addition, our suppliers pass along rising costs to us in the form of higher prices. We

have implemented cost control measures to curb increases in operating costs and expenses. We have generally offset

increases in operating costs by increasing reimbursement for services, expanding services and reducing costs in other areas.

However, we cannot predict our ability to cover or offset future cost increases, particularly any increases in our cost of

providing health insurance benefits to our employees.

27

### Geographic Data

The information below provides an overview of our operations in certain markets as of September 30, 2024.

*Texas*. We operated 13 acute care hospital facilities (including one managed hospital that is owned by The University of

Texas Health Science Center at Tyler, an affiliate of The University of Texas System) with 1,436 licensed beds that serve the

areas of Tyler, Amarillo and Killeen, Texas. For the nine months ended September 30, 2024, we generated 36.4% of our total

revenue in the Texas market.

*Oklahoma*. We operated eight acute care hospital facilities with 1,173 licensed beds that serve the area of Tulsa, Oklahoma.

For the nine months ended September 30, 2024, we generated 24.8% of our total revenue in the Oklahoma market.

*New Mexico*. We operated five acute care hospital facilities with 619 licensed beds that serve the areas of Albuquerque and

Roswell, New Mexico. For the nine months ended September 30, 2024, we generated 14.6% of our total revenue in the New

Mexico market.

*New Jersey*. We operated two acute care hospital facilities with 476 licensed beds that serve the areas of Montclair and

Westwood, New Jersey. For the nine months ended September 30, 2024, we generated 10.2% of our total revenue in the New

Jersey market.

### Other Industry Trends

The demand for healthcare services continues to be impacted by the following trends:

- A growing focus on healthcare spending by consumers, employers and insurers, who are actively seeking lower-cost

care solutions;

- A shift in patient volumes from inpatient to outpatient settings due to technological advancements and demand for

care that is more convenient, affordable and accessible;

- The growing aged population, which requires greater chronic disease management and higher-acuity treatment; and
- Ongoing consolidation of providers and insurers across the healthcare industry.

Additionally, the healthcare industry, particularly acute care hospitals, continues to be subject to ongoing regulatory

uncertainty. Changes in federal or state healthcare laws, regulations, funding policies or reimbursement practices, especially

those involving reductions to government payment rates or limitations on what providers may charge, could significantly

impact future revenue and operations. For example, the No Surprises Act prohibits providers from charging patients an

amount beyond the in-network cost sharing amount for services rendered by out-of-network providers, subject to limited

exceptions. For services for which balance billing is prohibited, the No Surprises Act includes provisions that may limit the

amounts received by out-of-network providers from health plans. Any reduction in the rates that we can charge or amounts

we can receive for our services will reduce our total revenue and our operating margins.

### Results of Operations

### Revenue and Volume Trends

Our revenue depends upon inpatient occupancy levels, ancillary services and therapy programs ordered by physicians and

provided to patients, the volume of outpatient procedures and the charges and negotiated payment rates for such services.

Total revenue is comprised of net patient service revenue and other revenue. We recognize patient service revenue in the

period in which we provide services. Patient service revenue includes amounts we estimate to be reimbursable by Medicare,

Medicaid and other payors under provisions of cost or prospective reimbursement formulas in effect. The amounts we receive

from these payors are generally less than the established billing rates, and we report patient service revenue net of these

differences (contractual adjustments) at the time we render the services. We also report patient service revenue net of the

effects of other arrangements where we are reimbursed for services at less than established rates, including certain self-pay

adjustments provided to uninsured patients. We also record estimated implicit price concessions (based primarily on

28

historical collection experience) related to uninsured accounts to record self-pay revenue at the estimated amount expected to

be collected.

Total revenue for the three months ended September 30, 2024 increased $72.1 million, or 5.2%, compared to the same prior

year period. The increase in total revenue for the three months ended September 30, 2024 consisted of an increase in adjusted

admissions of 3.8% and an increase in net patient service revenue per adjusted admission of 0.9%. The increase in adjusted

admissions was primarily driven by growth in admissions of 6.4% compared to the same prior year period. Outpatient

surgeries increased 0.2% compared to the same prior year period. Outpatient surgery growth was limited, in part, by ongoing

service line optimization efforts that resulted in strategic reallocation of resources from high volume, low margin procedures,

such as certain dental, otolaryngology and ophthalmology procedures, to alternate higher margin service lines. The increase

in net patient service revenue per adjusted admission was attributable to a combination of a favorable payor mix and

improved service mix as a result of ongoing service line optimization efforts, partially offset by a decrease in supplemental

funding as compared to the same prior year period.

Total revenue for the nine months ended September 30, 2024 increased $296.3 million, or 7.3%, compared to the same prior

year period. The increase in total revenue for the nine months ended September 30, 2024 consisted of an increase in adjusted

admissions of 3.5% and an increase in net patient service revenue per adjusted admission of 3.6%. The increase in adjusted

admissions reflected growth in admissions of 5.6%, partially offset by a decrease in outpatient surgeries of 1.7% compared to

the same prior year period, driven, in part, by ongoing service line optimization efforts that resulted in strategic reallocation

of resources from high volume, low margin procedures, such as certain dental, otolaryngology and ophthalmology

procedures, to alternate higher margin service lines. The increase in net patient service revenue per adjusted admission was

attributable to a combination of a favorable payor mix, improved service mix as a result of ongoing service line optimization

efforts, and an increase in supplemental funding as compared to the same prior year period.

A key competitive strength and a significant component of our growth strategy has been our well-established and

differentiated JV model, which has resulted in partnerships with premier academic medical centers, large not-for-profit

hospital systems, community physicians, and a community foundation. During the three months ended September 30, 2024

and 2023, total revenue related to these JVs was $429.9 million and $394.8 million, respectively, which represented 29.7%

and 28.7%, respectively, of our total revenue for such periods. During the nine months ended September 30, 2024 and 2023,

total revenue related to these entities was $1,281.0 million and $1,203.4 million, respectively, which represented 29.4% and

29.6%, respectively, of our total revenue for such periods.

The following table provides the sources of our total revenue by payor:

|  | Three Months Ended September 30, 2024 | 2023 | Nine Months Ended September 30, 2024 | 2023 |
| --- | ---: | ---: | ---: | ---: |
| Medicare | 38.7% | 39.0% | 39.3% | 39.6% |
| Medicaid | 10.2% | 11.0% | 10.6% | 11.3% |
| Other managed care | 43.3% | 42.7% | 43.0% | 42.2% |
| Self-pay and other | 5.5% | 5.5% | 5.2% | 5.1% |
| Net patient service revenue | 97.7% | 98.2% | 98.1% | 98.2% |
| Other revenue | 2.3% | 1.8% | 1.9% | 1.8% |
| Total revenue | 100.0% | 100.0% | 100.0% | 100.0% |

29

### Operating Results Summary for the Three Months Ended September 30, 2024

The following table sets forth the consolidated results of our operations expressed in dollars and as a percentage of total

revenue for the periods presented.

*(Unaudited, dollars in thousands)*

|  | Three Months Ended September 30, 2024 Amount% |  | 2023 Amount% |  |
| --- | ---: | ---: | ---: | ---: |
| Total revenue | $1,449,817 | 100.0% | $1,377,727 | 100.0% |
| Expenses: |  |  |  |  |
| Salaries and benefits | 635,223 | 43.8% | 595,580 | 43.2% |
| Professional fees | 274,223 | 18.9% | 246,540 | 17.9% |
| Supplies | 251,862 | 17.4% | 249,548 | 18.1% |
| Rents and leases | 26,410 | 1.8% | 24,506 | 1.8% |
| Rents and leases, related party | 37,249 | 2.6% | 36,413 | 2.6% |
| Other operating expenses | 117,700 | 8.2% | 124,642 | 9.1% |
| Interest expense | 14,629 | 1.0% | 19,041 | 1.4% |
| Depreciation and amortization | 36,771 | 2.5% | 35,488 | 2.6% |
| Loss on extinguishment and modification of debt | 1,490 | 0.1% | — | 0.0% |
| Other non-operating gains | (2,807) | (0.2)% | — | 0.0% |
| Total operating expenses | 1,392,750 | 96.1% | 1,331,758 | 96.7% |
| Income before income taxes | 57,067 | 3.9% | 45,969 | 3.3% |
| Income tax expense | 11,062 | 0.7% | 7,261 | 0.5% |
| Net income | 46,005 | 3.2% | 38,708 | 2.8% |
| Net income attributable to noncontrolling interests | 19,683 | 1.4% | 17,870 | 1.3% |
| Net income attributable to Ardent Health Partners, Inc. | $26,322 | 1.8% | $20,838 | 1.5% |

30

### Operating Results Summary for the Nine Months Ended September 30, 2024

The following table sets forth, for the periods indicated, the consolidated results of our operations expressed in dollars and as

a percentage of total revenue for the periods presented.

*(Unaudited, dollars in thousands)*

|  | Nine Months Ended September 30, 2024 Amount% |  | 2023 Amount% |  |
| --- | ---: | ---: | ---: | ---: |
| Total revenue | $4,359,783 | 100.0% | $4,063,449 | 100.0% |
| Expenses: |  |  |  |  |
| Salaries and benefits | 1,880,790 | 43.1% | 1,785,939 | 44.0% |
| Professional fees | 810,820 | 18.6% | 715,111 | 17.6% |
| Supplies | 769,034 | 17.6% | 743,713 | 18.3% |
| Rents and leases | 76,251 | 1.7% | 73,230 | 1.8% |
| Rents and leases, related party | 111,413 | 2.6% | 108,914 | 2.7% |
| Other operating expenses | 354,851 | 8.2% | 342,026 | 8.3% |
| Government stimulus income | — | 0.0% | (8,463) | (0.2)% |
| Interest expense | 52,050 | 1.2% | 55,854 | 1.4% |
| Depreciation and amortization | 108,434 | 2.5% | 104,860 | 2.6% |
| Loss on extinguishment and modification of debt | 3,388 | 0.1% | — | 0.0% |
| Other non-operating gains | (3,062) | (0.1)% | (522) | 0.0% |
| Total operating expenses | 4,163,969 | 95.5% | 3,920,662 | 96.5% |
| Income before income taxes | 195,814 | 4.5% | 142,787 | 3.5% |
| Income tax expense | 36,997 | 0.9% | 24,591 | 0.6% |
| Net income | 158,817 | 3.6% | 118,196 | 2.9% |
| Net income attributable to noncontrolling interests | 62,678 | 1.4% | 60,139 | 1.5% |
| Net income attributable to Ardent Health Partners, Inc. | $96,139 | 2.2% | $58,057 | 1.4% |

31

The following table provides information on certain drivers of our total revenue:

| Operating Statistics | Three Months Ended September 30, 2024 | % Change | 2023 | Nine Months Ended September 30, 2024 | % Change | 2023 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Total revenue (in thousands) | $1,449,817 | 5.2% | $1,377,727 | $4,359,783 | 7.3% | $4,063,449 |
| Hospitals operated (at period end) (1) | 30 | (3.2)% | 31 | 30 | (3.2)% | 31 |
| Licensed beds (at period end) (2) | 4,287 | (0.8)% | 4,323 | 4,287 | (0.8)% | 4,323 |
| Utilization of licensed beds (3) | 46% | 4.5% | 44% | 46% | 2.2% | 45% |
| Admissions (4) | 39,568 | 6.4% | 37,191 | 116,995 | 5.6% | 110,754 |
| Adjusted admissions (5) | 86,833 | 3.8% | 83,643 | 254,909 | 3.5% | 246,298 |
| Inpatient surgeries (6) | 8,871 | 0.5% | 8,826 | 26,829 | 0.3% | 26,751 |
| Outpatient surgeries (7) | 23,220 | 0.2% | 23,164 | 69,201 | (1.7)% | 70,417 |
| Emergency room visits (8) | 161,343 | 2.6% | 157,182 | 475,212 | 3.7% | 458,160 |
| Patient days (9) | 182,023 | 4.8% | 173,687 | 540,196 | 2.6% | 526,634 |
| Total encounters (10) | 1,482,655 | 7.5% | 1,378,599 | 4,304,097 | 4.7% | 4,109,144 |
| Average length of stay (11) | 4.60 | (1.5)% | 4.67 | 4.62 | (2.7)% | 4.75 |
| Net patient service revenue per adjusted admission (12) | $16,312 | 0.9% | $16,174 | $16,784 | 3.6% | $16,206 |

(1) “Hospitals operated (at period end).” This metric represents the total number of hospitals operated by us at the end of the applicable period, irrespective of

whether the hospital real estate is (i) owned by us, (ii) leased by us or (iii) held through a controlling interest in a JV. This metric includes the managed clinical

operations of the hospital at UT Health North Campus in Tyler, Texas (“UT Health North Campus Tyler”), a hospital owned by The University of Texas Health

Science Center at Tyler (“UTHSCT”), an affiliate of The University of Texas System. Since we only manage the clinical operations of UT Health North

Campus Tyler, the financial results of such entity are not consolidated under Ardent Health Partners, Inc.

On April 30, 2024, we closed UT Health East Texas Specialty Hospital, a long-term acute care hospital (the “LTAC Hospital”) in Tyler, Texas. The LTAC

Hospital's inventory and fixed assets were transferred or repurposed to be used by our other hospitals. The LTAC Hospital had 36 licensed patient beds and

accounted for approximately $0.0 million and $2.2 million of total revenue and a pre-tax loss of $0.2 million and $0.5 million for the three months ended

September 30, 2024 and 2023, respectively, and approximately $2.4 million and $8.0 million of total revenue and a pre-tax loss of $0.8 million and $0.5 million

for the nine months ended September 30, 2024 and 2023, respectively.

(2) “Licensed beds (at period end).” This metric represents the total number of beds for which the appropriate state agency licenses a facility, regardless of whether

the beds are actually available for patient use.

(3) “Utilization of licensed beds.” This metric represents a measure of the actual utilization of our inpatient facilities, computed by (i) dividing patient days by the

number of days in each period, and (ii) further dividing that number by average licensed beds, which is calculated by dividing total licensed beds (at period end)

by the number of days in the period, multiplied by the number of days in the period the licensed beds were in existence.

(4) “Admissions.” This metric represents the number of patients admitted for inpatient treatment during the applicable period.

(5) “Adjusted admissions.” This metric is used by management as a general measure of combined inpatient and outpatient volume. Adjusted admissions provides

management with a key performance indicator that considers both inpatient and outpatient volumes by applying an inpatient volume measure (admissions) to a

ratio of gross inpatient and outpatient revenue to gross inpatient revenue. Gross inpatient and outpatient revenue reflect gross inpatient and outpatient charges

prior to estimated contractual adjustments, uninsured discounts, implicit price concessions, and other discounts. The calculation of adjusted admissions is

summarized as follows:

Adjusted Admissions = Admissions x (Gross Inpatient Revenue + Gross Outpatient Revenue)

Gross Inpatient Revenue

(6) “Inpatient surgeries.” This metric represents the number of surgeries performed on patients who have been admitted to our hospitals. Pain management, c-

sections, and certain diagnostic procedures are excluded from inpatient surgeries.

(7) “Outpatient surgeries.” This metric represents the number of surgeries performed on patients who have not been admitted to our hospitals. Pain management, c-

sections, and certain diagnostic procedures are excluded from outpatient surgeries.

(8) “Emergency room visits.” This metric represents the total number of patients provided with emergency room treatment during the applicable period.

(9) “Patient days.” This metric represents the total number of days of care provided to patients admitted to our hospitals during the applicable period.

(10) “Total encounters.” This metric represents the total number of events where healthcare services are rendered resulting in a billable event during the applicable

period. This includes both hospital and ambulatory patient interactions.

(11) “Average length of stay.” This metric represents the average number of days admitted patients stay in our hospitals.

(12) “Net patient service revenue per adjusted admission.” This metric represents net patient service revenue divided by adjusted admissions for the applicable

period. Net patient service revenue reflects gross inpatient and outpatient charges less estimated contractual adjustments, uninsured discounts, implicit price

concessions, and other discounts.

32

### Overview of the Three Months Ended September 30, 2024

Total revenue for the three months ended September 30, 2024 increased $72.1 million, or 5.2%, compared to the same prior

year period. The increase in total revenue for the three months ended September 30, 2024 consisted of an increase in adjusted

admissions of 3.8% and an increase in net patient service revenue per adjusted admission of 0.9%. The increase in adjusted

admissions was primarily driven by growth in admissions of 6.4% compared to the same prior year period. Outpatient

surgeries increased 0.2% compared to the same prior year period. Outpatient surgery growth was limited, in part, by ongoing

service line optimization efforts that resulted in strategic reallocation of resources from high volume, low margin procedures,

such as certain dental, otolaryngology and ophthalmology procedures, to alternate higher margin service lines. The increase

in net patient service revenue per adjusted admission was attributable to a combination of a favorable payor mix and

improved service mix as a result of ongoing service line optimization efforts, partially offset by a decrease in supplemental

funding as compared to the same prior year period.

Total operating expenses increased $61.0 million for the three months ended September 30, 2024 compared to the same prior

year period due to higher patient volumes but decreased 0.6% as a percentage of total revenue. The decrease in total operating

expenses, as a percentage of total revenue, was driven by decreases in other operating expenses and supplies, as percentages

of total revenue, compared to the same prior year period. The decrease in other operating expenses, as a percentage of total

revenue, was primarily attributable to reduced provider assessments associated with various governmental supplemental

revenue programs during the three months ended September 30, 2024 compared to the same prior year period. The decrease

in supplies expense, as a percentage of net revenue, was driven by ongoing service line optimization efforts. The decrease in

total operating expense, as a percentage of total revenue, was partially offset by an increase in professional fees, as a

percentage of total revenue, due to higher costs for hospital-based providers as well as increased costs for revenue cycle

management services due to increased cash collections during the three months ended September 30, 2024, compared to the

same prior year period.

### Overview of the Nine Months Ended September 30, 2024

Total revenue for the nine months ended September 30, 2024 increased $296.3 million, or 7.3%, compared to the same prior

year period. The increase in total revenue for the nine months ended September 30, 2024 consisted of an increase in adjusted

admissions of 3.5% and an increase in net patient service revenue per adjusted admission of 3.6%. The increase in adjusted

admissions reflected growth in admissions of 5.6% compared to the same prior year period, partially offset by a decrease in

outpatient surgeries of 1.7% compared to the same prior year period, driven, in part, by ongoing service line optimization

efforts that resulted in strategic reallocation of resources from high volume, low margin procedures, such as certain dental,

otolaryngology and ophthalmology procedures, to alternate higher margin service lines. The increase in net patient service

revenue per adjusted admission was attributable to a combination of a favorable payor mix, improved service mix as a result

of ongoing service line optimization efforts, and an increase in supplemental funding as compared to the same prior year

period.

Total operating expenses increased $243.3 million for the nine months ended September 30, 2024 compared to the same prior

year period due to higher patient volumes but decreased 1.0% as a percentage of total revenue. The decrease in total operating

expenses, as a percentage of total revenue, was driven by decreases in salaries and benefits and supplies, as percentages of

total revenue, compared to the same prior year period. The decrease in salaries and benefits, as a percentage of total revenue,

was primarily due to a decrease in contract labor expense of $26.0 million during the nine months ended September 30, 2024

compared to the same prior year period. The decrease in supplies expense, as a percentage of total revenue, was driven by

ongoing service line optimization efforts during the nine months ended September 30, 2024 compared to the same prior year

period. The decrease in total operating expense, as a percentage of total revenue, was partially offset by an increase in

professional fees, as a percentage of total revenue, driven by higher costs for hospital-based providers and an increase in costs

for revenue cycle management services due to increased cash collections during the nine months ended September 30, 2024,

compared to the same prior year period.

### Comparison of the Three Months Ended September 30, 2024 and 2023

*Total revenue —* Total revenue for the three months ended September 30, 2024 increased $72.1 million, or 5.2%, compared

to the same prior year period. The increase in total revenue for the three months ended September 30, 2024 consisted of an

increase in adjusted admissions of 3.8% and an increase in net patient service revenue per adjusted admission of 0.9%. The

increase in adjusted admissions was primarily driven by growth in admissions of 6.4% compared to the same prior year

33

period. Outpatient surgeries increased 0.2% compared to the same prior year period. Outpatient surgery growth was limited,

in part, by ongoing service line optimization efforts that resulted in strategic reallocation of resources from high volume, low

margin procedures, such as certain dental, otolaryngology and ophthalmology procedures, to alternate higher margin service

lines. The increase in net patient service revenue per adjusted admission was attributable to a combination of a favorable

payor mix and improved service mix as a result of ongoing service line optimization efforts, partially offset by a decrease in

supplemental funding as compared to the same prior year period.

*Salaries and benefits —* Salaries and benefits, as a percentage of total revenue, were 43.8% for the three months ended

September 30, 2024 compared to 43.2% for the same prior year period. The increase in salaries and benefits, as a percentage

of total revenue, was driven by an increase in equity-based compensation of $8.0 million.

*Professional fees —* Professional fees, as a percentage of total revenue, were 18.9% for the three months ended September

30, 2024 compared to 17.9% for the same prior year period. The increase in professional fees, as a percentage of total

revenue, reflected higher costs for hospital-based providers as well as increased expenses for revenue cycle management

services due to increased cash collections during the three months ended September 30, 2024.

*Supplies —* Supplies, as a percentage of total revenue, were 17.4% for the three months ended September 30, 2024 compared

to 18.1% for the same prior year period. The decrease in supplies, as a percentage of total revenue, was attributable to

ongoing service line optimization efforts and execution on various supply chain cost reduction initiatives, including improved

inventory management, standardized surgical supply procurement and strategic sourcing.

*Rents and leases —* Rents and leases were $26.4 million and $24.5 million for the three months ended September 30, 2024

and 2023, respectively.

*Rents and leases, related party —* Rents and leases, related party, consists of lease expense related to the Master Lease with

Ventas ("Ventas Master Lease"), under which we lease 10 of our facilities, and other lease agreements with Ventas for certain

medical office buildings. Rents and leases, related party were $37.2 million and $36.4 million for the three months ended

September 30, 2024 and 2023, respectively.

*Other operating expenses —* Other operating expenses, as a percentage of total revenue, were 8.2% for the three months

ended September 30, 2024 compared to 9.1% for the same prior year period. Other operating expenses are comprised

primarily of repairs and maintenance, utility, insurance (including professional liability insurance) and provider assessments.

The change in other operating expenses, as a percentage of total revenue, was primarily driven by a decrease in provider

assessments associated with various governmental supplemental revenue programs during the three months ended September

30, 2024, compared to the same prior year period.

*Interest expense —* Interest expense was $14.6 million and $19.0 million for the three months ended September 30, 2024 and

2023, respectively.

*Loss on extinguishment and modification of debt —* On September 18, 2024, we executed an amendment to our Term Loan B

Credit Agreement. In connection with this transaction, we incurred a loss on the debt extinguishment of $0.3 million related

to the write-off of existing deferred financing costs and original issue discounts and transaction costs of $1.2 million related

to the modification of debt during the three months ended September 30, 2024.

*Other non-operating gains —* Other non-operating gains were $2.8 million and $0.0 million for the three months ended

September 30, 2024 and 2023, respectively. The increase in other non-operating gains was primarily due to the recognition of

insurance recovery proceeds of $2.9 million during the three months ended September 30, 2024 related to the Cybersecurity

Incident.

*Income tax expense —* We recorded income tax expense of $11.1 million, which equates to an effective tax rate of 19.4%, for

the three months ended September 30, 2024 compared to income tax expense of $7.3 million, which equates to an effective

tax rate of 15.8%, for the same prior year period. The increase in income tax expense was primarily driven by an increase in

income before income taxes attributable to Ardent Health Partners, Inc., which resulted in an increase in taxes at the federal

statutory rate during the three months ended September 30, 2024 compared to the same prior year period. Additionally, the

effective tax rate was further impacted by permanent differences resulting from the disallowance of certain equity-based

compensation incurred during the during the three months ended September 30, 2024.

34

*Net income attributable to noncontrolling interests —* Net income attributable to noncontrolling interests of $19.7 million for

the three months ended September 30, 2024 compared to $17.9 million for the same prior year period consisted primarily of

$19.7 million and $17.0 million of net income attributable to minority partners’ interests in hospitals and ambulatory services

that are owned and operated though limited liability companies and consolidated by us for the three months ended September

30, 2024 and 2023, respectively. Income from operations before income taxes related to these limited liability companies was

$68.6 million and $60.3 million for the three months ended September 30, 2024 and 2023, respectively. The remaining

portion of net income attributable to noncontrolling interests for the three months ended September 30, 2023 consisted of net

income attributable to ALH Holdings, LLC’s (a subsidiary of Ventas, a related party) minority interest in AHP Health

Partners, our direct subsidiary.

### Comparison of the Nine Months Ended September 30, 2024 and 2023

*Total revenue —* Total revenue for the nine months ended September 30, 2024 increased $296.3 million, or 7.3%, compared

to the same prior year period. The increase in total revenue for the nine months ended September 30, 2024 consisted of an

increase in adjusted admissions of 3.5% and an increase in net patient service revenue per adjusted admission of 3.6%. The

increase in adjusted admissions reflected growth in admissions of 5.6% compared to the same prior year period. The growth

in admissions was partially offset by a decrease in outpatient surgeries of 1.7% compared to the same prior year period

driven, in part, by ongoing service line optimization efforts that resulted in strategic reallocation of resources from high

volume, low margin procedures, such as certain dental, otolaryngology and ophthalmology procedures, to alternate higher

margin service lines. The increase in net patient service revenue per adjusted admission was attributable to a combination of a

favorable payor mix, improved service mix as a result of ongoing service line optimization efforts, and an increase in

supplemental funding as compared to the same prior year period.

*Salaries and benefits —* Salaries and benefits, as a percentage of total revenue, were 43.1% for the nine months ended

September 30, 2024 compared to 44.0% for the same prior year period. The decrease in salaries and benefits, as a percentage

of total revenue, was primarily attributable to a decrease in contract labor expense of $26.0 million due to a combination of

reduced contract labor rates and lower utilization, driven by ongoing recruiting and retention initiatives. Total contract labor

expenses, as a percentage of total salaries and benefits, were 4.2% and 5.9% for the nine months ended September 30, 2024

and 2023, respectively.

*Professional fees —* Professional fees, as a percentage of total revenue, were 18.6% for the nine months ended September 30,

2024 compared to 17.6% for the same prior year period. The increase in professional fees, as a percentage of total revenue,

reflected higher costs for hospital-based providers as well as increased expenses for revenue cycle management services due

to increased cash collections during the nine months ended September 30, 2024.

*Supplies —* Supplies, as a percentage of total revenue, were 17.6% for the nine months ended September 30, 2024 compared

to 18.3% for the same prior year period. The decrease in supplies expense, as a percentage of total revenue, was attributable

to ongoing service line optimization efforts and execution on various supply chain cost reduction initiatives, including

improved inventory management, standardized surgical supply procurement and strategic sourcing.

*Rents and leases —* Rents and leases were $76.3 million and $73.2 million for the nine months ended September 30, 2024

and 2023, respectively.

*Rents and leases, related party —* Rents and leases, related party, consists lease expense related to the Ventas Master Lease,

under which we lease 10 of our hospitals, and other lease agreements with Ventas for certain medical office buildings. Rents

and leases, related party were $111.4 million and $108.9 million for the nine months ended September 30, 2024 and 2023,

respectively.

*Other operating expenses —* Other operating expenses, as a percentage of total revenue, were 8.2% for the nine months ended

September 30, 2024 compared to 8.3% for the same prior year period.

*Government stimulus income —* Government stimulus income was $0.0 million and $8.5 million for the nine months ended

September 30, 2024 and 2023, respectively.

*Interest expense —* Interest expense was $52.1 million and $55.9 million for the nine months ended September 30, 2024 and

2023, respectively.

35

*Loss on extinguishment and modification of debt —* On June 26, 2024, we executed an amendment to our ABL Credit

Agreement and prepaid $100.0 million of the outstanding principal on our Term Loan B Facility. Additionally, on September

18, 2024, we executed an amendment to our Term Loan B Credit Agreement. In connection with these transactions, we

incurred a loss on the debt extinguishment of $1.8 million related to the write-off of existing deferred financing costs and

original issue discounts and transaction costs of $1.2 million related to the modification of debt during the nine months ended

September 30, 2024.

*Other non-operating gains —* Other non-operating gains were $3.1 million and $0.5 million for the nine months ended

September 30, 2024 and 2023, respectively. The increase in other non-operating gains was primarily due to the recognition of

a gain on insurance recovery proceeds of $2.9 million during the nine months ended September 30, 2024 related to the

Cybersecurity Incident.

*Income tax expense —* We recorded income tax expense of $37.0 million, which equates to an effective tax rate of 18.9%, for

the nine months ended September 30, 2024 compared to income tax expense of $24.6 million, which equates to an effective

tax rate of 17.2%, for the same prior year period. The increase in income tax expense was primarily driven by an increase in

income before income taxes attributable to Ardent Health Partners, Inc., which resulted in an increase in taxes at the federal

statutory rate during the nine months ended September 30, 2024 compared to the same prior year period. Additionally, the

effective tax rate was further impacted by permanent differences resulting from the disallowance of certain equity-based

compensation incurred during the nine months ended September 30, 2024

*Net income attributable to noncontrolling interests —* Net income attributable to noncontrolling interests of $62.7 million for

the nine months ended September 30, 2024 compared to $60.1 million for the same prior year period consisted primarily of

$59.8 million and $57.5 million of net income attributable to minority partners’ interests in hospitals and ambulatory services

that are owned and operated though limited liability companies and consolidated by us for the nine months ended September

30, 2024 and 2023, respectively. Income from operations before income taxes related to these limited liability companies was

$207.0 million and $198.4 million for the nine months ended September 30, 2024 and 2023, respectively. The remaining

portion of net income attributable to noncontrolling interests consists of net income attributable to ALH Holdings, LLC’s (a

subsidiary of Ventas, a related party) minority interest in AHP Health Partners, our direct subsidiary, prior to the ALH

Contribution in July 2024.

36

### Supplemental Non-GAAP Information

We have included certain financial measures that have not been prepared in a manner that complies with U.S. generally

accepted accounting principles (“GAAP”), including Adjusted EBITDA and Adjusted EBITDAR. We define these terms as

follows:

### Performance Measure

- “Adjusted EBITDA” is defined as net income plus (i) provision for income taxes, (ii) interest expense and (iii)

depreciation and amortization expense (or EBITDA), as adjusted to deduct noncontrolling interest earnings, and

excludes the effects of losses on the extinguishment and modification of debt; other non-operating losses (gains);

Cybersecurity Incident recoveries, net of incremental information technology and litigation costs; restructuring, exit

and acquisition-related costs; expenses incurred in connection with the implementation of Epic Systems (“Epic”),

our integrated health information technology system, equity-based compensation expense, and loss (income) from

disposed operations. See “Supplemental Non-GAAP Performance Measure.”

### Valuation Measure

- “Adjusted EBITDAR” is defined as Adjusted EBITDA further adjusted to add back rent expense payable to real

estate investment trusts ("REITs"), which consists of rent expense pursuant to the Ventas Master Lease, lease

agreements associated with the MOB Transactions (as defined below) and a lease arrangement with Medical

Properties Trust, Inc. ("MPT") for Hackensack Meridian Mountainside Medical Center. See “Supplemental Non-

GAAP Valuation Measure.”

### Supplemental Non-GAAP Performance Measure

Adjusted EBITDA is a non-GAAP performance measure used by our management and external users of our financial

statements, such as investors, analysts, lenders, rating agencies and other interested parties, to evaluate companies in our

industry.

Adjusted EBITDA is a performance measure that is not defined under GAAP and is presented in this Quarterly Report

because our management considers it an important analytical indicator that is commonly used within the healthcare industry

to evaluate financial performance and allocate resources. Further, our management believes that Adjusted EBITDA is a

useful financial metric to assess our operating performance from period to period by excluding certain material non-cash

items and unusual or non-recurring items that we do not expect to continue in the future and certain other adjustments we

believe are not reflective of our ongoing operations and our performance.

Because not all companies use identical calculations, our presentation of the non-GAAP measure may not be comparable to

other similarly titled measures of other companies.

While we believe this is a useful supplemental performance measure for investors and other users of our financial

information, you should not consider the non-GAAP measure in isolation or as a substitute for net income or any other items

calculated in accordance with GAAP. Adjusted EBITDA has inherent material limitations as a performance measure, because

it adds back certain expenses to net income, resulting in those expenses not being taken into account in the performance

measure. We have borrowed money, so interest expense is a necessary element of our costs. Because we have material capital

and intangible assets, depreciation and amortization expense are necessary elements of our costs. Likewise, the payment of

taxes is a necessary element of our operations. Because Adjusted EBITDA excludes these and other items, it has material

limitations as a measure of our performance.

37

The following table presents a reconciliation of Adjusted EBITDA, a performance measure, to net income, determined in

accordance with GAAP:

*(in thousands)*

|  | Three Months Ended September 30, 2024 | 2023 | Nine Months Ended September 30, 2024 | 2023 |
| --- | ---: | ---: | ---: | ---: |
| Net income | $46,005 | $38,708 | $158,817 | $118,196 |
| Adjusted EBITDA Addbacks: |  |  |  |  |
| Income tax expense | 11,062 | 7,261 | 36,997 | 24,591 |
| Interest expense, net | 14,629 | 19,041 | 52,050 | 55,854 |
| Depreciation and amortization | 36,771 | 35,488 | 108,434 | 104,860 |
| Noncontrolling interest earnings | (19,683) | (17,870) | (62,678) | (60,139) |
| Loss on extinguishment and modification of debt | 1,490 | — | 3,388 | — |
| Other non-operating losses (gains) (a) | 47 | — | (208) | (522) |
| Cybersecurity Incident recoveries, net (b) | (4,976) | — | (4,976) | — |
| Restructuring, exit and acquisition-related costs (c) | 3,796 | 1,511 | 11,694 | 11,473 |
| Epic expenses (d) | 485 | 437 | 1,500 | 1,415 |
| Equity-based compensation | 8,135 | 181 | 8,873 | 723 |
| Loss (income) from disposed operations | 3 | 3 | 1,989 | (65) |
| Adjusted EBITDA | $97,764 | $84,760 | $315,880 | $256,386 |

(a) Other non-operating losses (gains) include gains and losses realized on certain non-recurring events or events that are non-operational in

nature, including gains realized on certain asset divestitures.

(b) Cybersecurity Incident recoveries, net represents insurance recovery proceeds associated with the Cybersecurity Incident, net of

incremental information technology and litigation costs.

(c) Restructuring, exit and acquisition-related costs represent (i) enterprise restructuring costs, including severance costs related to work

force reductions of $3.2 million and $1.3 million for the three months ended September 30, 2024 and 2023, respectively, and

$10.1 million and $10.6 million for the nine months ended September 30, 2024 and 2023, respectively, (ii) penalties and costs incurred

for terminating pre-existing contracts at acquired facilities of $0.2 million and $0.1 million for the three months ended September 30,

2024 and 2023, respectively, and $0.6 million and $0.6 million for the nine months ended September 30, 2024 and 2023, respectively,

and (iii) third-party professional fees and expenses, salaries and benefits, and other internal expenses incurred in connection with

potential and completed acquisitions of $0.4 million and $0.1 million for the three months ended September 30, 2024 and 2023,

respectively, and $1.0 million and $0.3 million for the nine months ended September 30, 2024 and 2023, respectively.

(d) Epic expenses consist of various costs incurred in connection with the implementation of Epic, our health information technology

system. These costs included professional fees of $0.5 million and $0.4 million for the three months ended September 30, 2024 and 2023,

respectively, and $1.5 million and $1.4 million for the nine months ended September 30, 2024 and 2023, respectively. Epic expenses do

not include the ongoing costs of the Epic system.

38

### Liquidity and Capital Resources

### Liquidity

Our primary sources of liquidity are available cash and cash equivalents, cash flows from our operations and available

borrowings under our ABL Facilities (as defined below). Our primary cash requirements are our operating expenses, the

service of our debt, capital expenditures on our existing properties, acquisitions of hospitals and other healthcare facilities,

and distributions to noncontrolling interests. We believe the combination of cash flow from operations and available cash and

borrowings will be adequate to meet our short-term liquidity needs. Our ability to make scheduled payments of principal, pay

interest on, or refinance, our indebtedness, pay distributions or fund planned capital expenditures will depend on our ability to

generate cash in the future. This ability is, to a certain extent, subject to general economic, financial, competitive, legislative,

regulatory and other factors that are beyond our control.

At September 30, 2024, we had total cash and cash equivalents of $563.1 million and available liquidity of $851.2 million.

Our available liquidity was comprised of $563.1 million of total cash and cash equivalents plus $288.1 million in available

capacity under the ABL Credit Agreement, which is reduced by outstanding borrowings and outstanding letters of credit. In

June 2024, we amended the ABL Credit Agreement to increase commitments available thereunder by $100.0 million and

extended its maturity date to June 26, 2029. See "Senior Secured Credit Facilities" for additional information. At September

30, 2024, our net leverage ratio, as calculated under our ABL Credit Agreement and Term Loan B Credit Agreement, was

1.6x, and our lease-adjusted net leverage ratio was 3.5x. Our lease adjusted net leverage is calculated as net debt as of

September 30, 2024, plus 8.0x trailing twelve month REIT rent expense as of the end of the third quarter of 2024, divided by

the trailing twelve month Adjusted EBITDAR as of September 30, 2024.

During the nine months ended September 30, 2024 and 2023, we received and recognized $0.0 million and $8.5 million,

respectively, of cash distributions from the Public Health and Social Services Emergency Fund (“Provider Relief Fund”), a

provision of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”), and other state and local programs.

For additional information regarding distributions from the Provider Relief Fund and the CARES Act, refer to Note 2 to our

unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2024.

### Cash Flows

The following table summarizes certain elements of the statements of cash flows (in thousands):

|  | Nine Months Ended September 30, 2024 | 2023 |
| --- | ---: | ---: |
| Net cash provided by operating activities | $195,457 | $154,199 |
| Net cash used in investing activities | (115,016) | (81,277) |
| Net cash provided by (used in) financing activities | 45,124 | (84,370) |

### Operating Activities

Cash flows provided by operating activities for the nine months ended September 30, 2024 totaled $195.5 million compared

to $154.2 million for the same prior year period. The increase in operating cash flows during the nine months ended

September 30, 2024 was primarily attributable to an increase in net income of $40.6 million.

### Investing Activities

Cash flows used in investing activities for the nine months ended September 30, 2024 totaled $115.0 million compared to

$81.3 million for the same prior year period. Capital expenditures for non-acquisitions were $106.2 million and $80.0

million for the nine months ended September 30, 2024 and 2023, respectively.

### Financing Activities

Cash flows provided by financing activities for the nine months ended September 30, 2024 totaled $45.1 million compared to

cash flows used in financing activities of $84.4 million for the same prior year period. Cash flows provided by financing

activities for the nine months ended September 30, 2024 included IPO proceeds, net of underwriting discounts and

39

commissions, of $208.7 million, proceeds from insurance financing arrangements of $10.8 million, and proceeds from long-

term debt of $3.6 million. Cash flows provided by financing activities were partially offset by payments of principal on long-

term debt of $106.3 million, which included a prepayment of $100.0 million on the $877.5 million outstanding borrowings

under our Term Loan B Facility, and payments of principal on insurance financing arrangements of $7.4 million. Cash flows

provided by financing activities for the nine months ended September 30, 2024 were partially offset by distributions paid to

noncontrolling interests of $53.1 million.

Cash flows used in financing activities for the nine months ended September 30, 2023 totaled $84.4 million and included

distributions paid to noncontrolling interests of $50.7 million, redemption of equity attributable to non-controlling interest of

$26.0 million, payments of principal on long-term debt of $10.5 million, and payments of principal on insurance financing

arrangements of $15.9 million, which were partially offset by proceeds from insurance financing arrangements of $24.7

million.

### Capital Expenditures

We make significant, targeted investments to maintain and modernize our facilities, introduce new technologies, and expand

our service offerings. We expect to finance future capital expenditures with internally generated and borrowed funds. Capital

expenditures for property and equipment were $106.2 million and $80.0 million for the nine months ended September 30,

2024 and 2023, respectively.

### Ventas Master Lease

Effective August 4, 2015, we sold the real property for ten of our hospitals to Ventas, which is a related party as, prior to our

IPO, it was a common unit holder of Ardent Health Partners, LLC and owned shares of common stock of AHP Health

Partners and had a representative serving on our board of managers. Concurrent with this transaction, we entered into a 20-

year master lease agreement that expires in August 2035 (with a renewal option for an additional ten years) to lease back the

real estate. We lease ten of our hospitals pursuant to the Ventas Master Lease. As of September 30, 2024, following the

consummation of the IPO and the underwriters’ exercise of their option to purchase additional shares, Ventas beneficially

owned approximately 6.5% of our outstanding common stock.

The Ventas Master Lease includes a number of significant operating and financial restrictions, including requirements that we

maintain a minimum portfolio coverage ratio of 2.2x and a guarantor fixed charge coverage ratio of 1.2x and do not exceed a

guarantor net leverage ratio of 6.75x. In addition, the Relative Rights Agreement entered into by and among Ventas, the

5.75% Senior Notes trustee and the administrative agents under our Senior Secured Credit Facilities (as defined below) in

connection with the series of debt transactions completed during the year ended 2021 to refinance our then-existing debt,

among other things, (i) sets forth the relative rights of Ventas and the administrative agents with respect to the properties and

collateral related to the Ventas Master Lease and securing our Senior Secured Credit Facilities, (ii) caps the amount of

indebtedness incurred or guaranteed by our subsidiaries that are tenants under the Ventas Master Lease ("Tenants") (together

with such Tenants’ guarantees of the notes and the Senior Secured Credit Facilities and all other indebtedness incurred or

guaranteed by such Tenants) at $375.0 million and (iii) imposes certain incurrence tests on the incurrence of additional

indebtedness by such Tenants and by us.

We recorded rent expense of $37.2 million and $36.4 million for the three months ended September 30, 2024 and 2023,

respectively, and $111.4 million and $108.9 million for the nine months ended September 30, 2024 and 2023, respectively,

related to the Ventas Master Lease and other lease agreements with Ventas for certain medical office buildings.

### Senior Secured Credit Facilities

Effective July 8, 2021, we entered into the ABL Credit Agreement, which was amended most recently on June 26, 2024. The

ABL Credit Agreement (as so amended) consists of a $325.0 million senior secured asset-based revolving credit facility with

a five year maturity, comprised of (i) a $275.0 million non-UT Health East Texas borrowers tranche (the “non-UT Health

East Texas ABL Facility”) and (ii) a $50.0 million UT Health East Texas borrowers tranche available to our AHS East Texas

Health System, LLC subsidiary and certain of its subsidiaries (the “UT Health East Texas ABL Facility” and, together with

the non-UT Health East Texas ABL Facility, the “ABL Facilities”), each subject to a borrowing base. Effective as of June 26,

40

2024, we amended the ABL Credit Agreement to increase the commitments available under the non-UT Health East Texas

ABL Facility from $175.0 million to $275.0 million and to extend the maturity of the ABL Facilities to June 26, 2029.

Effective August 24, 2021, we entered into the Term Loan B Facility. The credit agreement governing the Term Loan B

Facility provided funding up to a principal amount of $900.0 million. The Term Loan B Facility has a seven year maturity

with principal due in quarterly installments of 0.25% of the initial $900.0 million principal amount (subject to certain

reductions from time to time as a result of the application of prepayments), with the remaining balance due upon maturity of

the Term Loan B Facility. Effective June 8, 2023, we amended the Term Loan B Credit Agreement to replace LIBOR with

Term SOFR (each as defined in the amended Term Loan B Credit Agreement) as the reference interest rate and establish

further successor rates. On June 26, 2024, we prepaid $100.0 million of the $877.5 million outstanding borrowings under the

Term Loan B Facility using cash on hand. Additionally, on September 18, 2024, we executed an amendment to reprice our

Term Loan B Credit Agreement. The repricing reduced the applicable interest rate by 50 basis points from Term SOFR plus

3.25% to Term SOFR plus 2.75% and eliminated the credit spread adjustment. No modifications were made to the maturity

of the loans as a result of the repricing and all other terms were substantially unchanged.

We refer to the ABL Facilities and the Term Loan B Facility collectively herein as the “Senior Secured Credit Facilities.”

Subject to certain exceptions, the ABL Facilities are secured by first priority liens over substantially all of our and each

guarantor’s accounts and other receivables, chattel paper, deposit accounts and securities accounts, general intangibles,

instruments, investment property, commercial tort claims and letters of credit relating to the foregoing, along with books,

records and documents, and proceeds thereof (the “ABL Priority Collateral”), and a second priority lien over substantially all

of our and each guarantor’s other assets (including all of the capital stock of the domestic guarantors and first priority

mortgage liens on any fee-owned real property valued in excess of $5,000,000) (the “Term Priority Collateral”). The

obligations of the UT Health East Texas ABL Facility are not secured by the assets of the subsidiaries that are also Tenants

and certain other subsidiaries related to the Tenants. The obligations under the Term Loan B Facility and the ABL Facilities

in excess of the maximum aggregate dollar cap amount permitted to be guaranteed by the Tenants are not secured by the

assets of the Tenants.

The Term Loan B Facility is secured by a first priority lien on the Term Priority Collateral and a second priority lien on the

ABL Priority Collateral. Certain excluded assets are not included in the Term Priority Collateral or the ABL Priority

Collateral. The obligations under the Term Loan B Facility and the ABL Facilities in excess of the maximum aggregate dollar

cap amount permitted to be guaranteed by the Tenants are not secured by the assets of the Tenants.

Borrowings under the Term Loan B Facility bear interest at a rate per annum equal to, at our option, either (i) the base rate

determined by reference to the highest of (a) the federal funds effective rate plus 0.50%, (b) the “Prime Rate” in the United

States for U.S. dollar loans as publicly announced by Bank of America from time to time, and (c) Term SOFR plus 1.00% per

annum, in each case, plus an applicable margin, or (ii) Term SOFR (not to be less than 0.50% per annum) for the interest

period selected, plus an applicable margin. Under the Term Loan B Facility, the applicable margin is 2.50% for base rate

borrowings and 3.50% for Term SOFR borrowings. Following the completion of the IPO, the applicable margin for the

remaining outstanding borrowings under the Term Loan B Facility was automatically reduced by 0.25% per annum.

Principal under the Term Loan B Facility is due in quarterly installments of 0.25% of the $900.0 million initial principal

amount (subject to certain reductions from time to time as a result of the application of prepayments), with the remaining

balance due upon maturity. The ABL Facilities do not require installment payments.

At the election of the borrowers under the applicable ABL Facility loan, the interest rate per annum applicable to loans under

the ABL Facilities is based on a fluctuating rate of interest determined by reference to either (i) the base rate plus an

applicable margin or (ii) Term SOFR (not to be lower than 0.00% per annum) for the interest period selected, plus an

applicable margin. The applicable margin is determined based on the percentage of the average daily availability of the

applicable ABL Facility. For the non-UT Health East Texas ABL Facility loan, the applicable margin ranges from 0.5% to

1.0% for base rate borrowings and 1.5% to 2.0% for Term SOFR borrowings. The applicable margin for the UT Health East

Texas ABL Facility loan ranges from 1.5% to 2.0% for base rate borrowings and 2.5% to 3.0% for Term SOFR borrowings.

Subject to certain exceptions (including with regard to the ABL Priority Collateral), thresholds and reinvestment rights, the

Term Loan B Facility is subject to mandatory prepayments with respect to:

41

- 100% of net cash proceeds of issuances of debt by AHP Health Partners or any of its restricted subsidiaries that are

not permitted by the Term Loan B Facility;

- 100% (with step-downs to 50% and 0%, based upon achievement of specified senior secured net leverage ratio

levels) of net cash proceeds of certain asset sales;

- 50% (with step-downs to 25% and 0%, based upon achievement of specified senior secured net leverage ratio

levels), net of certain voluntary prepayments and secured indebtedness, of annual excess cash flow of AHP Health

Partners and its subsidiaries commencing with the fiscal year ended December 31, 2022; and

- net cash proceeds received in connection with any exercise of the purchase option of the loans by Ventas under the

Relative Rights Agreement.

### 5.750% Senior Notes due 2029

AHP Health Partners, our direct wholly-owned subsidiary, issued the 5.75% Senior Notes in an exempt offering pursuant to

Rule 144A and Regulation S under the Securities Act that was completed on July 8, 2021. The terms of the 5.75% Senior

Notes are governed by an indenture, dated as of July 8, 2021 (the “Indenture”), among AHP Health Partners, us and certain of

AHP Health Partners' wholly-owned domestic subsidiaries, as guarantors, and U.S. Bank Trust Company, National

Association, as trustee. The Indenture provides that the 5.75% Senior Notes are general senior unsecured obligations of AHP

Health Partners, which are unconditionally guaranteed on a senior unsecured basis by us and certain subsidiaries of AHP

Health Partners.

The 5.75% Senior Notes mature on July 15, 2029 and bear interest at a rate of 5.750% per annum, payable semi-annually, in

cash in arrears, on January 15 and July 15 of each year, commencing on January 15, 2022.

AHP Health Partners may redeem the 5.75% Senior Notes, in whole or in part, at any time and from time to time, (1) prior to

July 15, 2024, at a redemption price equal to 100% of the principal amount of the 5.75% Senior Notes, plus accrued and

unpaid interest, if any, to the redemption date, plus a “make-whole” premium as set forth in the Indenture and the 5.75%

Senior Notes; and (2) on and after July 15, 2024, at the redemption prices set forth below, plus accrued and unpaid interest, if

any, to the redemption date, subject to compliance with certain conditions:

| Date (if redeemed during the 12 month period beginning on July 15 of the years indicated below) | Percentage |
| --- | ---: |
| 2024 | 102.875% |
| 2025 | 101.438% |
| 2026 and thereafter | 100.000% |

In addition, prior to July 15, 2024, AHP Health Partners could have redeemed on one or more occasions up to 40% of the

original aggregate principal amount of the 5.75% Senior Notes with the net proceeds of one or more equity offerings, as

described in the Indenture, at a redemption price equal to 105.750% of the principal amount thereof, plus accrued and unpaid

interest, if any, to the redemption date, provided that at least 50% of the aggregate original principal amount of the 5.75%

Senior Notes issued under the Indenture remained outstanding after each such redemption and the redemption occurred

within 180 days after the closing of such equity offering.

42

### Contractual Obligations and Contingencies

The following table provides a summary of our commitments and contractual obligations for debt, minimum lease payment

obligations under non-cancelable leases and other obligations as of September 30, 2024 (in thousands):

|  | Payments Due by Period Total | Less than 1 Year | 1-3 Years | 3-5 Years | After 5 Years |
| --- | ---: | ---: | ---: | ---: | ---: |
| Long-term debt obligations, with interest | $1,464,532 | $25,332 | $179,197 | $933,820 | $326,183 |
| Deferred financing obligations, with interest | 15,449 | 2,601 | 11,456 | 1,392 | — |
| Operating leases | 3,014,528 | 49,452 | 384,184 | 361,894 | 2,218,998 |
| Estimated self-insurance liabilities | 185,073 | 40,976 | 39,439 | 61,618 | 43,040 |
| Total | $4,679,582 | $118,361 | $614,276 | $1,358,724 | $2,588,221 |

Outstanding letters of credit are required principally by certain insurers and states to collateralize our workers' compensation

programs and self-insured retentions associated with our professional and general liability insurance programs. As of

September 30, 2024, we maintained outstanding letters of credit of approximately $40.1 million, which included interest of

$3.2 million.

### Supplemental Non-GAAP Valuation Measure

Adjusted EBITDAR is a commonly used non-GAAP valuation measure used by our management, research analysts,

investors and other interested parties to evaluate and compare the enterprise value of different companies in our industry.

Adjusted EBITDAR excludes: (1) certain material noncash items and unusual or non-recurring items that we do not expect to

continue in the future; (2) certain other adjustments that do not impact our enterprise value; and (3) rent expense payable to

our REITs. We operate 30 acute care hospitals, 12 of which we lease from two REITs, Ventas and MPT, pursuant to long-

term lease agreements. Additionally, during 2022, we completed the sale of 18 medical office buildings to Ventas in

exchange for $204.0 million and concurrently entered into agreements to lease the real estate back from Ventas over a 12-

year initial term with eight options to renew for additional five-year terms (the "MOB Transactions"). Our management views

the long-term lease agreements with Ventas and MPT, as well as the MOB Transactions, as more like financing arrangements

than true operating leases, with the rent payable to such REITs being similar to interest expense. As a result, our capital

structure is different than many of our competitors, especially those whose real estate portfolio is predominately owned and

not leased. Excluding the rent payable to such REITs allows investors to compare our enterprise value to those of other

healthcare companies without regard to differences in capital structures, leasing arrangements and geographic markets, which

can vary significantly among companies. Our management also uses Adjusted EBITDAR as one measure in determining the

value of prospective acquisitions or divestitures. Finally, financial covenants in certain of our lease agreements, including the

Ventas Master Lease, use Adjusted EBITDAR as a measure of compliance. Adjusted EBITDAR does not reflect our cash

requirements for leasing commitments. As such, our presentation of Adjusted EBITDAR should not be construed as a

performance or liquidity measure.

Because not all companies use identical calculations, our presentation of the non-GAAP measure may not be comparable to

other similarly titled measures of other companies.

While we believe this is a useful supplemental valuation measure for investors and other users of our financial information,

you should not consider the non-GAAP measure in isolation or as a substitute for net income or any other items calculated in

accordance with GAAP. Adjusted EBITDAR has inherent material limitations as a valuation measure, because it adds back

certain expenses to net income, resulting in those expenses not being taken into account in the valuation measure. The

payment of taxes and rent is a necessary element of our valuation. Because Adjusted EBITDAR excludes these and other

items, it has material limitations as a measure of our valuation.

43

The following table presents a reconciliation of Adjusted EBITDAR, a valuation measure, to net income, determined in

accordance with GAAP:

*(in thousands)*

|  | Three Months Ended September 30, 2024 | Nine Months Ended September 30, 2024 |
| --- | ---: | ---: |
| Net income | $46,005 | $158,817 |
| Adjusted EBITDAR Addbacks: |  |  |
| Income tax expense | 11,062 | 36,997 |
| Interest expense, net | 14,629 | 52,050 |
| Depreciation and amortization | 36,771 | 108,434 |
| Noncontrolling interest earnings | (19,683) | (62,678) |
| Loss on extinguishment and modification of debt | 1,490 | 3,388 |
| Other non-operating losses (gains) (a) | 47 | (208) |
| Cybersecurity Incident recoveries, net (b) | (4,976) | (4,976) |
| Restructuring, exit and acquisition-related costs (c) | 3,796 | 11,694 |
| Epic expenses (d) | 485 | 1,500 |
| Equity-based compensation | 8,135 | 8,873 |
| Loss from disposed operations | 3 | 1,989 |
| Rent expense payable to REITs (e) | 40,056 | 119,826 |
| Adjusted EBITDAR | $137,820 | $435,706 |

(a) Other non-operating losses (gains) include gains and losses realized on certain non-recurring events or events that are non-operational in

nature, including gains realized on certain asset divestitures.

(b) Cybersecurity Incident recoveries, net represents insurance recovery proceeds associated with the Cybersecurity Incident, net of

incremental information technology and litigation costs.

(c) Restructuring, exit and acquisition-related costs represent (i) enterprise restructuring costs, including severance costs related to work

force reductions of $3.2 million and $10.1 million for the three and nine months ended September 30, 2024, respectively, (ii) penalties

and costs incurred for terminating pre-existing contracts at acquired facilities of $0.2 million and $0.6 million for the three and nine

months ended September 30, 2024, respectively, and (iii) third-party professional fees and expenses, salaries and benefits, and other

internal expenses incurred in connection with potential and completed acquisitions of $0.4 million and $1.0 million for the three and nine

months ended September 30, 2024, respectively.

(d) Epic expenses consist of various costs incurred in connection with the implementation of Epic, our health information technology

system. These costs included professional fees of $0.5 million and $1.5 million for the three and nine months ended September 30, 2024,

respectively. Epic expenses do not include the ongoing costs of the Epic system.

(e) Rent expense payable to REITs consists of rent expense of $37.2 million and $111.4 million related to the Ventas Master Lease and lease

agreements associated with the MOB Transactions with Ventas for the three and nine months ended September 30, 2024, respectively,

and rent expense of $2.8 million and $8.4 million related to a lease arrangement with MPT for the lease of Hackensack Meridian

Mountainside Medical Center for the three and nine months ended September 30, 2024, respectively.

### Critical Accounting Policies and Estimates

The preparation of financial statements in accordance with GAAP requires us to make estimates and assumptions that affect

reported amounts and related disclosures. We regularly evaluate the accounting policies and estimates we use. In general, we

base the estimates on historical experience and on assumptions that we believe to be reasonable, given the particular

circumstances in which we operate. Actual results may vary from those estimates. We consider our critical accounting

estimates to be those that (i) involve significant judgments and uncertainties, (ii) require estimates that are more difficult for

management to determine, and (iii) may produce materially different outcomes under different conditions or when using

different assumptions.

Refer to *Management's Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting*

*Policies and Estimates* and our audited consolidated financial statements and notes thereto as of and for the year ended

December 31, 2023 included in our Final Prospectus for a complete and comprehensive discussion of the accounting policies

and related estimates we believe are most critical to understanding our consolidated financial statements, financial condition

and results of operations and that require complex management judgment and assumptions or involve uncertainties. These

critical accounting estimates include revenue recognition, risk management and self-insured liabilities, income taxes, and

44

unit-based compensation. There have been no changes to our critical accounting policies or their application since the date of

our Final Prospectus.

45

## Market risk

As filed, 2,176 characters.

We are subject to market risk from exposure to changes in interest rates based on our financing, investing and cash

management activities. We do not, however, hold or issue financial instruments or derivatives for trading or speculative

purposes. At September 30, 2024, the following components of our Senior Secured Credit Facilities bore interest at variable

rates at specified margins above either the agent bank’s alternate base rate or Term SOFR: (i) a $900.0 million, seven-year

term loan; and (ii) a $325.0 million, five-year asset-based revolving credit facility. As of September 30, 2024, we had

outstanding variable rate debt of $774.0 million.

At September 30, 2024, we had interest rate swap agreements with notional amounts totaling $521.1 million, expiring June

30, 2026. Under these swap agreements, we are required to make monthly fixed rate payments at annual rates ranging from

1.47% to 1.48% and the counterparties are obligated to make monthly floating rate payments to us based on one-month Term

SOFR, each subject to a floor of 0.39%.

Although changes in the alternate base rate or Term SOFR would affect the cost of funds borrowed in the future, we believe

the effect, if any, of reasonably possible near-term changes in interest rates on our variable rate debt on our consolidated

financial position, results of operations or cash flows would not be material. Based on the outstanding borrowings and impact

of the interest rate swaps in place at September 30, 2024, a one percent change in the interest rate would result in a $2.5

million increase or decrease in our annual interest expense.

We currently believe we have adequate liquidity to fund operations during the near term through the generation of operating

cash flows, cash on hand and access to our Senior Secured Credit Facilities. Our ability to borrow funds under our ABL

Facilities is subject to, among other things, the financial viability of the participating financial institutions. While we do not

anticipate any of our current lenders defaulting on their obligations, we are unable to provide assurance that any particular

lender will not default at a future date.

## Controls and procedures

As filed, 1,766 characters.

### (a) Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of

the end of the period covered by this Quarterly Report, the effectiveness of our disclosure controls and procedures. Based on

this evaluation of our disclosure controls and procedures as of September 30, 2024, our principal executive officer and

principal financial officer concluded that our disclosure controls and procedures as of such date were effective at the

reasonable assurance level. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under

the Securities Exchange Act of 1934, as amended (the “Exchange Act”), means controls and other procedures of a company

that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under

the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and

forms. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide

only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the

cost-benefit relationship of possible controls and procedures.

### (b) Changes in Internal Control over Financial Reporting

During the quarter ended September 30, 2024, there have been no changes in our internal control over financial reporting, as

such term is defined in Rules 13a-15(f) and 15(d)-15(f) promulgated under the Exchange Act, that have materially affected,

or are reasonably likely to materially affect, our internal control over financial reporting.

46

## Risk factors

As filed, 265 characters.

There have been no material changes to our risk factors that we believe are material to our business, results of operations and

financial condition from the risk factors previously disclosed in the section entitled “Risk factors” included in the Final

Prospectus.

Filed Nov 7, 2024.
Source: SEC EDGAR, the filing index for accession 0001756655-24-000017. Last ingested by Listed: Nov 13, 2026, 16:00 ET. No prices; not investment advice.
